July 7th, 2014
HEAT-PPCI: Heparin Beats Bivalirudin in Primary PCI
Larry Husten, PHD
Although there is broad consensus in the medical community that primary PCI is the best treatment for MI patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has […]
NEJM Journal Watch — Recent Cardiology Articles- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Sessions 2024
- Does the Coronary Sinus Reducer Decrease Ischemia and Angina in Patients with Stable Coronary Disease?
- Plozasiran Reduced Triglyceride Levels in Severe Hypertriglyceridemia